Poor
Needs Revision
Patient Risk:
Moderate
Summary
The response contains multiple high-level immunization/vaccine-response claims that are not supported by the provided Cosentyx label excerpts; only limited label support exists (immunizations guidance and avoidance of live vaccines). Several general statements about vaccine effectiveness magnitude, timing, and immune readouts are not present in the supplied labeling.
Category Scores
Accurate Statements
Patients should ask their clinician before getting vaccinated if they are considering a live vaccine.
Label 5.7 (Immunizations): COSENTYX may alter immune response to live vaccines; avoid use of live vaccines in patients treated with COSENTYX.
Live-attenuated vaccines carry additional considerations during immunomodulating therapy.
Label 5.7 (Immunizations): COSENTYX may alter patient's immune response to live vaccines; avoid use of live vaccines in patients treated with COSENTYX.
The main practical concerns after vaccination on secukinumab are whether vaccine effectiveness is reduced and whether certain vaccine types are safe with IL-17 blockade.
Partially supported by Label 5.7 (Immunizations): COSENTYX may alter immune response to live vaccines; avoid live vaccines. Label excerpt does not support the 'vaccine effectiveness is reduced' generalization.
Unsupported Statements
Cosentyx (secukinumab) blocks interleukin-17A (IL-17A).
No mechanism-of-action statement provided in the supplied excerpts.
Because secukinumab modulates parts of the immune response, it can change how well the body responds to vaccines in general.
Label excerpt 5.7 only states COSENTYX may alter immune response to live vaccines and advises avoiding live vaccines; it does not support generalized effects on all vaccines.
Post-vaccination antibody levels and/or T-cell responses may be different in people taking secukinumab than in people not taking it.
No provided label language describing antibody/T-cell response differences.
The exact effect of secukinumab on vaccine responses depends on the vaccine type and on the specific immune readout being measured.
No provided label language about vaccine-type-dependent effects on immune readouts.
For IL-17 pathway inhibitors, studies have reported that vaccine responses can be reduced or altered compared with untreated controls.
No provided label excerpt contains statements about 'IL-17 pathway inhibitors' studies comparing to untreated controls or reduction in vaccine responses.
Vaccine responses with IL-17 pathway inhibitors are not always reduced to the same degree across different vaccines.
No provided label language addressing degree differences across vaccines.
Some regimens produce measurable immune responses even when taking IL-17 pathway inhibitors.
No provided label language about measurable immune responses during therapy.
The magnitude of vaccine response reduction with IL-17 pathway inhibitors may be lower compared with untreated controls.
No provided label language quantifying or describing magnitude of vaccine-response reduction.
The direction and size of the effect of IL-17 pathway inhibitors on vaccine responses vary by vaccine platform.
No provided label language describing direction/size variations by platform.
The direction and size of the effect of IL-17 pathway inhibitors on vaccine responses vary by the timing of vaccination relative to starting therapy.
No provided label language about timing relative to starting therapy affecting vaccine responses.
Effects of IL-17 pathway blockade on vaccine responses can differ by vaccine type.
No provided label language describing differences by vaccine type beyond live vaccine avoidance.
Responses to non-live (inactivated or protein-based) vaccines may still occur with IL-17 pathway inhibitors.
Label excerpt 5.7 does not provide statements about non-live vaccines.
Responses to non-live vaccines may be blunted with IL-17 pathway inhibitors.
Label excerpt 5.7 does not provide statements about non-live vaccine response blunting.
Even if immune responses are reduced, vaccination can still provide protection in people taking secukinumab.
No provided label language about reduced immune responses leading to retained protection, or any protection statements.
Vaccination can provide protection especially over time and with booster strategies.
No provided label language about time course or boosters and protection.
For an individual patient, protection depends on vaccine type.
No provided label language about individual protection determinants.
For an individual patient, protection depends on the patient’s disease background.
No provided label language addressing disease background as determinant of protection.
For an individual patient, protection depends on prior vaccination or infection history.
No provided label language addressing prior vaccination/infection history as determinant.
For an individual patient, protection depends on baseline immune function.
No provided label language addressing baseline immune function as determinant.
Clinicians may weigh the benefit of staying on therapy against the goal of maximizing vaccine response and may coordinate timing with dose schedules.
Label excerpt 5.7 advises considering completion of age-appropriate immunizations prior to initiating therapy and avoiding live vaccines; it does not support coordination/timing with dose schedules to maximize vaccine response.
Immune response strength is influenced by when vaccination occurs relative to immunomodulator dosing.
No provided label language about vaccination timing relative to dosing affecting immune response strength.
Vaccinating before starting a biologic tends to support a stronger baseline response than vaccinating after the biologic has begun.
No provided label language describing comparative vaccine response strength before vs after starting therapy.
Vaccinating before starting a biologic supports a stronger baseline response because the immune system is less suppressed when vaccine antigens are presented.
Mechanistic explanation and comparative assertion not present in supplied label excerpts.
General vaccine side effects (such as sore arm, fever, and fatigue) are expected and are not unique to secukinumab.
No provided label language about expected general vaccine side effects.
The key question after vaccination in immunomodulated patients is the strength of the immune response and adherence to vaccine safety guidance.
No provided label language framing 'key question' or immune-response-strength wording; label 5.7 only addresses live vaccine avoidance and immunization completion consideration.
Patients should ask their clinician before getting vaccinated if they are planning vaccination soon after starting Cosentyx.
Label excerpt 5.7 advises considering completion of age-appropriate immunizations prior to initiating therapy; it does not explicitly instruct patients to ask about vaccination 'soon after starting' in this manner.
Patients should ask their clinician before getting vaccinated if they want guidance on optimal timing and boosters for a specific vaccine.
Label excerpt 5.7 does not mention booster optimization or optimal timing guidance beyond completing age-appropriate immunizations prior to initiating therapy.
Contradictions
Low
AI Statement
Live-attenuated vaccines may be avoided depending on prescribing guidance and clinical judgment.
Label Reference
Label 5.7 states: Avoid use of live vaccines in patients treated with COSENTYX.
Important Omissions
The label-specific instruction to avoid live vaccines in patients treated with COSENTYX is not emphasized as an explicit 'avoid' directive in multiple places; several statements broaden effects to all vaccines and immunologic readouts without label support.
Importance:
Moderate
Label guidance to consider completion of all age-appropriate immunizations prior to initiating therapy is not directly stated in the response (beyond generalized timing claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported general claims about effects on non-live vaccines and vaccine immune responses could mislead to overgeneralize vaccine safety/effectiveness. The live-vaccine avoidance concept is supported, but some wording dilutes the label's clear avoidance guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple vaccine-response claims (e.g., non-live vaccine blunting, immune readouts, magnitude/direction by platform/timing) are not supported by the provided COSENTYX label excerpts; only limited label support exists regarding live vaccine avoidance and considering completion of immunizations prior to starting therapy.
Suggested Improvement
Restrict statements to label-supported immunization guidance: consider completing age-appropriate immunizations prior to initiating COSENTYX and avoid live vaccines in patients treated with COSENTYX. Remove or qualify unsupported generalizations about IL-17 blockade effects on non-live vaccines, antibody/T-cell readouts, magnitude/direction by platform/timing, and protection over time/boosters.